Cullen Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Cullen Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-19,200	Closed	-$1.14M	–	179
2015 Q2	$1.14M	Sell	19,200 -22,500	-54%	-$1.39M	0.04%	122
2015 Q1	$2.6M	Sell	41,700 -21,500	-34%	-$1.25M	0.07%	90
2014 Q4	$3.63M	Buy	63,200 +1,700	+3%	+$94.7K	0.1%	80
2014 Q3	$3.31M	Buy	61,500 +20,000	+48%	+$1.06M	0.09%	81
2014 Q2	$2.17M	Buy	41,500 +5,950	+17%	+$304K	0.06%	83
2014 Q1	$1.88M	Buy	+35,550	New	+$1.64M	0.05%	88

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cullen Capital Management's TEVA Position: Q3 2015 in Review

Cullen Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2015, closing a stake of 19,200 shares — an estimated $1.14M sold.

Cullen Capital Management first reported a position in TEVA in Q1 2014 and held it in 6 quarters. The position peaked at $3.63M in Q4 2014. 823 funds tracked by Wall St. Rank hold TEVA as of Q3 2015.

Cullen Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Cullen Capital Management sold 19,200 Teva Pharmaceuticals shares in Q3 2015, an estimated $1.14M.
Cullen Capital Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 6 quarters.
Cullen Capital Management's Teva Pharmaceuticals position peaked at $3.63M in Q4 2014.
823 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2015.

Based on Cullen Capital Management's 13F filing for Q3 2015, filed 12 Nov 2015.